Opexa Therapeutics

From Deletionpedia.org: a home for articles deleted from Wikipedia
Jump to: navigation, search
This article was considered for deletion at Wikipedia on December 24 2013. This is a backup of Wikipedia:Opexa_Therapeutics. All of its AfDs can be found at Wikipedia:Special:PrefixIndex/Wikipedia:Articles_for_deletion/Opexa_Therapeutics, the first at Wikipedia:Wikipedia:Articles_for_deletion/Opexa_Therapeutics. Purge

Opexa Therapeutics Template:Nasdaq, formerly known as PharmaFrontiers, is a U.S. biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis, congestive heart failure, and diabetes. The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T cell vaccination technologies.


Founded in 2003, the company was originally known as PharmaFrontiers Corp. In October 2004 PharmaFrontiers acquired the privately held company Opexa Pharmaceuticals Inc.[1] In June 2006 the company changed its name to Opexa Therapeutics, Inc.[2]

In 2009 the company sold its stem cell technology to Novartis and focused all of its attention on the continuing development of Tovaxin.[3]

Research areas and products

Key products and research include:


Opexa Therapeutics is located in The Woodlands, Texas 30 mi north of Houston, Texas. The company has a 10200 sqft facility on 3 acre in The Woodlands.


External links